Editor: What To Know
- Building on the success of Cologuard and Oncotype DX, the company is investing in its product pipeline to take on some of the deadliest cancers and improve patient care.
- Conroy concluded, “Today is an important one in Exact’s history as we continue to lead cancer diagnostics and transform the future for millions of patients through earlier detection and treatment guidance.
- On behalf of everyone at Exact Sciences, I’d like to welcome the talented Thrive team and express my excitement for the future of our company.
January 5, 2020
Exact Sciences Corp. today announced that it has completed its previously announced acquisition of Thrive Earlier Detection Corp. (“Thrive”).
“Bringing Thrive into the Exact Sciences family marks a giant leap toward blood-based, multi-cancer screening becoming a reality and eventually the standard of care,” said Kevin Conroy, chairman and CEO of the company.
Conroy concluded, “Today is an important one in Exact’s history as we continue to lead cancer diagnostics and transform the future for millions of patients through earlier detection and treatment guidance. On behalf of everyone at Exact Sciences, I’d like to welcome the talented Thrive team and express my excitement for the future of our company.”
The company is a provider of cancer screening and diagnostic tests. The company pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, the company is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer.
